Palvella Therapeutics Inc
PVLA37.200USD
+0.650+1.78%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
410.00MMarket Cap
LossP/E TTM
More Details of Palvella Therapeutics Inc Company
Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.
Company Info
Ticker SymbolPVLA
Company namePalvella Therapeutics Inc
IPO dateDec 18, 2014
CEOMr. Wesley H. (Wes) Kaupinen
Number of employees14
Security typeOrdinary Share
Fiscal year-endDec 18
Address125 Strafford Ave
CityWAYNE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19087
Phone14842531461
Websitehttps://palvellatx.com/
Ticker SymbolPVLA
IPO dateDec 18, 2014
CEOMr. Wesley H. (Wes) Kaupinen
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 15
Updated: Tue, Jul 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kaupinen (Wesley H.)
14.54%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Frazier Life Sciences Management, L.P.
6.24%
Samsara BioCapital, LLC
6.15%
Other
60.31%
Shareholders
Shareholders
Proportion
Kaupinen (Wesley H.)
14.54%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Frazier Life Sciences Management, L.P.
6.24%
Samsara BioCapital, LLC
6.15%
Other
60.31%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.10%
Individual Investor
17.80%
Private Equity
9.95%
Venture Capital
6.15%
Investment Advisor
6.11%
Other Insider Investor
5.06%
Investment Advisor/Hedge Fund
3.02%
Research Firm
0.46%
Other
28.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
110
7.92M
71.64%
+1.45M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
2023Q3
161
703.90K
61.81%
-282.90K
2023Q2
173
831.24K
82.60%
-68.86K
2023Q1
202
592.51K
63.79%
-198.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Kaupinen (Wesley H.)
1.61M
14.54%
--
--
Apr 14, 2025
Suvretta Capital Management, LLC
714.46K
6.46%
--
--
Mar 31, 2025
BVF Partners L.P.
696.55K
6.3%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
690.01K
6.24%
+36.12K
+5.52%
Mar 31, 2025
Samsara BioCapital, LLC
679.49K
6.15%
--
--
Mar 31, 2025
Integrated Finance Group
559.95K
5.06%
+559.95K
--
Apr 14, 2025
Adams Street Partners, LLC
409.67K
3.71%
--
--
Mar 31, 2025
Millennium Management LLC
269.84K
2.44%
+269.84K
--
Mar 31, 2025
Nantahala Capital Management, LLC
250.06K
2.26%
--
--
Mar 31, 2025
Jenkins (George M)
196.69K
1.78%
+4.99K
+2.60%
Apr 14, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.17%
iShares Micro-Cap ETF
0.03%
Global X Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 ETF
0%
View more
ALPS Medical Breakthroughs ETF
Proportion0.17%
iShares Micro-Cap ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Date
Type
Ratio
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
